BCYC Valuation

Bicycle Therapeutics PLC

Add to Watchlist

Advanced Chart

7.490

-0.300(-3.850%)

Overview
Forecast
Valuation

BCYC Relative Valuation

BCYC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCYC is overvalued; if below, it's undervalued.

Historical Valuation

Bicycle Therapeutics PLC (BCYC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.16 is considered Undervalued compared with the five-year average of 44.25. The fair price of Bicycle Therapeutics PLC (BCYC) is between 9.25 to 29.39 according to relative valuation methord. Compared to the current price of 7.49 USD , Bicycle Therapeutics PLC is Undervalued By 19.06%.

Relative Value

Fair Zone

9.25-29.39

Current Price：7.49

19.06%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.68

P/B

Median3y

2.22

Median5y

3.36

-33.92

FCF Yield

Median3y

-11.36

Median5y

-8.11

Competitors Valuation Multiple

The average P/S ratio for BCYC's competitors is 4.89, providing a benchmark for relative valuation. Bicycle Therapeutics PLC Corp (BCYC) exhibits a P/S ratio of 14.16, which is 189.60% above the industry average. Given its robust revenue growth of -30.44%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

BCYC.O

Bicycle Therapeutics PLC